A major pharmaceutical trade publication has turned its spotlight on Forte Biosciences — and for celiac families, that attention matters more than it might first appear. The Pharma Letter published fresh coverage of Forte Biosciences following its $2.2 billion acquisition by argenx — a deal built entirely on autoimmune biology, and autoimmune biology sits at the center of celiac disease.
Celiac disease is, at its core, a case of the immune system misfiring. So is vitiligo — the skin condition that made Forte Biosciences worth $2.2 billion to argenx, as we covered when that acquisition was announced. And so is dermatitis herpetiformis, the intensely itchy, blistering skin rash that develops in roughly 15 to 25 percent of people with celiac disease. When pharmaceutical companies pour billions into understanding why the immune system attacks the body, their findings rarely stay siloed in a single condition. That is the thread worth pulling here.
What This Means for You
Celiac disease, vitiligo, and dermatitis herpetiformis all share immune system roots. Each involves the body’s T cells and inflammatory signaling going awry in ways that damage tissue. Drug mechanisms proven in one of these conditions frequently get tested in others — which means the research argenx and Forte are funding has downstream relevance for celiac patients, even when celiac is not the primary target.
For the roughly one in five celiac patients who develop dermatitis herpetiformis (DH), that overlap is not abstract — it is their daily reality. DH is caused by the same gluten-triggered immune response that damages the small intestine; it simply expresses on the skin instead. Current treatment options are a strict gluten-free diet (non-negotiable, just as in intestinal celiac) and, for some patients, the antibiotic dapsone, which carries real risks over long-term use. Newer autoimmune biologics — the class of drugs that argenx and Forte are developing — could eventually offer better options for DH patients who need management beyond diet alone.
More broadly, investment at this scale builds the scientific infrastructure that benefits all autoimmune patients. Advances in understanding immune tolerance and antibody-mediated tissue damage in vitiligo generate testable hypotheses for celiac researchers. The billions flowing into this space are not irrelevant to celiac families — they accelerate the whole field. As someone who reads every clinical update looking for what might eventually help my son and others like him, I pay attention to these adjacent stories precisely because today’s autoimmune breakthrough in one condition often becomes tomorrow’s therapeutic lead in another.
That said, I want to be clear about what this coverage does not mean. No Forte drug currently targets celiac disease directly. There is no Forte compound on the horizon for the small intestinal damage celiac patients experience. This is a story about adjacent science — important context, not a celiac breakthrough.
Key Takeaways
- Forte Biosciences, acquired by argenx for $2.2 billion, is developing drugs for autoimmune skin conditions — the same disease class as dermatitis herpetiformis, a skin manifestation of celiac disease.
- Dermatitis herpetiformis affects an estimated 15 to 25 percent of celiac patients and is driven by the same gluten-triggered immune response as intestinal celiac disease.
- No Forte compound directly targets celiac disease — but autoimmune research regularly produces spillover benefits across related conditions.
- The gluten-free diet remains the only proven treatment for both intestinal celiac disease and dermatitis herpetiformis.
- If you or a family member has celiac disease and develops an unexplained blistering skin rash, consult a dermatologist alongside your gastroenterologist — DH is frequently misdiagnosed.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
Autoimmune Conditions Share a Common Architecture
Celiac disease, vitiligo, and dermatitis herpetiformis are all driven by adaptive immune system dysfunction — the branch of immunity responsible for targeted responses, including antibody production and activation of T cells (immune cells that identify and attack specific targets). In a healthy immune system, T cells learn to tolerate the body’s own tissue. In autoimmune disease, that tolerance collapses.
In vitiligo, T cells attack melanocytes — the pigment-producing cells in skin. In celiac disease, tissue transglutaminase 2 (an enzyme abbreviated tTG2) is mistakenly targeted after gluten exposure, triggering inflammation along the small intestine’s lining. In dermatitis herpetiformis, the same gluten-triggered antibodies deposit in the skin and cause blistering. All three conditions represent a failure of immune tolerance — the system’s ability to distinguish the body’s own structures from genuine threats. Drug development that successfully restores that tolerance in one condition creates a blueprint worth testing in others.
How Forte’s Drug Class Works
Forte Biosciences’ lead compound — the asset argenx acquired primarily for its promise in vitiligo — is a monoclonal antibody (a lab-engineered protein designed to bind one specific molecular target). Monoclonal antibodies have transformed treatment of several autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. They work by precisely blocking the immune signals that trigger tissue damage.
Argenx built its reputation on efgartigimod, which targets the FcRn receptor (neonatal Fc receptor) — a protein that recycles antibodies in the bloodstream. Blocking FcRn accelerates clearance of harmful IgG antibodies (a class of immune proteins that drive many autoimmune attacks). This mechanism has shown benefit in conditions where IgG autoantibodies cause damage.
In celiac disease, the primary autoantibodies are IgA anti-tTG and IgA anti-deamidated gliadin peptide — both in the IgA class rather than IgG. That distinction means efgartigimod’s specific mechanism does not map directly onto celiac disease’s core pathology. But argenx’s expanding pipeline, now enriched by Forte’s assets, gives the company tools operating through multiple immune pathways, and that breadth is worth tracking.
Dermatitis Herpetiformis: The Celiac–Skin Connection
DH deserves special attention in this context because it is technically a skin manifestation of celiac disease, not a separate condition. IgA anti-epidermal transglutaminase antibodies — produced in response to gluten, mistaking skin proteins for a target — deposit in the dermal papillae (the uppermost layer of the skin’s connective tissue) and trigger the blistering rash characteristic of DH.
Because DH is gluten-driven, dietary treatment is essential. However, clearing DH skin lesions through the gluten-free diet alone can take 18 to 24 months — longer than intestinal healing typically requires. That extended timeline is why some patients use dapsone as a bridge treatment, even given its risks. A targeted biologic that modulates the IgA-mediated skin response with a cleaner side effect profile would be a genuine advance for DH patients. That drug does not exist yet. But the research pathways that could eventually produce it are receiving serious investment right now — and Forte Biosciences is one of the companies making that investment legible to the pharmaceutical world.
Related Coverage
References
- The Pharma Letter — Forte Biosciences (August 5, 2026): source
- Reunala T, et al. Dermatitis herpetiformis: a common extraintestinal manifestation of coeliac disease. Nutrients. 2018;10(5):602.
- Caproni M, et al. Dermatitis herpetiformis: pathogenesis, diagnosis, and therapy. Front Immunol. 2012;3:382.
- Fasano A, Catassi C. Celiac disease. N Engl J Med. 2012;367:2419–2426.